Literature DB >> 1553883

Proarrhythmic effects of antiarrhythmic drugs: evolving concepts.

J Morganroth1.   

Abstract

Although antiarrhythmic drugs are prescribed to reduce an arrhythmia, they may have the paradoxic effect of actually exacerbating that arrhythmia or causing new or more serious forms. This effect is known as "proarrhythmia." Proarrhythmic events may be segregated into those that occur "early" after therapy (within 30 days) and those that occur "late," after many months of therapy and manifesting as a fatal event (an increased risk of sudden cardiac death). The ability of the physician to predict drug proarrhythmia and its severity depends on the class of antiarrhythmic drug chosen, the type of ventricular arrhythmia to be treated, and the severity of the patient's underlying left ventricular dysfunction. Before the start of antiarrhythmic therapy, the physician must be able to quantitate the degree of proarrhythmic risk so that the benefit/risk ratio of such drug use can be determined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1553883     DOI: 10.1016/0002-8703(92)91073-a

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

1.  Resuscitation Outcomes Consortium-Amiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial.

Authors:  Peter J Kudenchuk; Siobhan P Brown; Mohamud Daya; Laurie J Morrison; Brian E Grunau; Tom Rea; Tom Aufderheide; Judy Powell; Brian Leroux; Christian Vaillancourt; Jonathan Larsen; Lynn Wittwer; M Riccardo Colella; Shannon W Stephens; Mark Gamber; Debra Egan; Paul Dorian
Journal:  Am Heart J       Date:  2014-03-01       Impact factor: 4.749

2.  Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.

Authors:  Witold Ruzyllo; Michal Tendera; Ian Ford; Kim M Fox
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.